After starting a pivotal trial last month, Sonus Pharmaceuticals Inc. now has secured a sweet deal for its cancer product Tocosol Paclitaxel, giving exclusive worldwide rights to Schering AG. (BioWorld Today)
Array BioPharma Inc. expanded its oncology collaboration with Genentech Inc. for the second time, securing a potential $50 million in additional research funding over the next three years. (BioWorld Today)
Lilly ICOS LLC plans to move tadalafil into a Phase III program for benign prostatic hyperplasia after it reached statistical significance in a Phase II proof-of-concept study. (BioWorld Today)
Once again beating consensus estimates, Genentech Inc. reported a strong third quarter driven by better-than-expected sales of Avastin and Herceptin, two products that are increasingly being prescribed off-label. (BioWorld Today)
As it prepares to bring two more of its internally discovered products into the clinic, Metabasis Therapeutics Inc. raised $41.3 million in a private placement of common stock and warrants. (BioWorld Today)
Cypress Bioscience Inc. lost more than half its value Thursday after announcing that a pivotal Phase III study of milnacipran missed its primary endpoint as a treatment for pain associated with fibromyalgia. (BioWorld Today)